WebIonis shares tumble 19% after Roche halts Phase 3 study for rare-disease drug Mar. 24, 2024 at 3:02 p.m. ET by Jaimy Lee Ionis Pharmaceuticals stock price target cut to $76 … Web13 apr. 2024 · Get undefined (IONS.OQ) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments
IONIS PHARMACEUTICALS INC stock forecast: up to 36.61 USD …
Web1 apr. 2024 · IONIS PHARMACEUTICALS INC stock price forecast for further price development up to 0. ... 1 day) and price target of 36.61 USD. Positive news sentiment. Short-term (time horizon: 2 weeks) IONIS PHARMACEUTICALS INC share price prediction for 2024-05-26 with daily closed price projections Key Facts Symbol IONS ISIN … Web9 aug. 2024 · Because Ionis is leading and conducting the Phase 3 development program, Ionis is recognizing the 55 percent of cost-share funding AstraZeneca is responsible for, net of Ionis' share of AstraZeneca's development expenses, as R&D revenue in the same period Ionis incurs the related development expenses. im a girly.com
Ionis Pharmaceuticals, Inc. (IONS) Stock Price, Quote & News
Web24 mrt. 2024 · After this action, Monia Brett P now owns 145,305 shares of Ionis Pharmaceuticals Inc., valued at $1,003,153 using the latest closing price. HOUGEN ELIZABETH L, the EVP, Finance & CFO of Ionis Pharmaceuticals Inc., sale 2,079 shares at $40.59 during a trade that took place back on Feb 06, which means that HOUGEN … Web14 aug. 2024 · Shares Sold Short 7.66 M Change from Last -6.15% Percent of Float 5.51% Stock Money Flow N/A PROFILE ( IONS) Ionis Pharmaceuticals, Inc. engages in the … Web22 feb. 2024 · R&D revenue for 2024 included $112 million from Biogen for advancing several neurology disease programs, $77 million from AstraZeneca for its share of the global Phase 3 development costs for eplontersen and $64 million from Roche for licensing and advancing IONIS-FB-L Rx, among other partner payments. im a girls girl im a boss in a mans world